Last reviewed · How we verify
Eastern Health, Canada — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 18F-2-fluoro-2-deoxy-D-glucose | 18F-2-fluoro-2-deoxy-D-glucose | phase 3 | Positron emission tomography (PET) imaging agent | Glucose transporter (GLUT1) and hexokinase | Oncology, Neurology, Cardiology |
Therapeutic area mix
- Oncology, Neurology, Cardiology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centre hospitalier de l'Université de Montréal (CHUM) · 1 shared drug class
- National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class
- Ochsner Health System · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Eastern Health, Canada:
- Eastern Health, Canada pipeline updates — RSS
- Eastern Health, Canada pipeline updates — Atom
- Eastern Health, Canada pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Eastern Health, Canada — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eastern-health-canada. Accessed 2026-05-16.